South Korea has developed a second stem cell treatment
A second stem-cell treatment, hearticellgram-ami, is expected to be approved this month after South Korea won approval for the world's first stem-cell treatment for coronary heart disease, yonhap news agency said.
South Korea's food and drug agency said it may approve production licenses for medi-post's cartilage regeneration drug Cartistem and Anterogen's anal fistula treatment Cuepistem and some others, by the middle of this month.
Medi-post's Cartistem is a drug specifically tailored to treat degenerative arthritis and damaged knee cartilage, based on stem cells extracted from umbilical cord blood, according to the report. It is worth noting that Cartistem does not use the patient's own stem cells, but other people's stem cells, so if the production license is obtained, it will be the world's first treatment drug produced using other people's stem cells. The advantage is that it can be mass produced.
Anterogen's Cuepistem is a drug created from stem cells taken from a patient's own adipose tissue to treat a complex clonogenic anal fistula.
- June 18, 2019The bacteria that caused the European outbreak may have originated from the ehec strain isolated in Germany in 2001, according to new research published by the bgi on June 5. The research team of the ...view
- March 25, 2019Researchers released laboratory research results at the American Heart Congress on the 24th. Stem cell therapy has shown positive effects on patients with heart injury, and patients with impaired hear...view
- May 16, 2019News on March 3, 2019 – A recent study,that was published in The Journal of Physiology, suggests that exercise may delay The growth of colon cancer cells. The study found that colon cancer cells grow...view